Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

GSK ditches ovarian cancer plans for Votrient

01.04.2014 / Fierce Pharma

GlaxoSmithKline said Monday that after reviewing data from a Phase III trial, it has withdrawn its application to the European Medicines Agency seeking to expand approval of Votrient to include women with advanced ovarian cancer.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: